Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
2.340
+0.020 (0.86%)
Apr 6, 2026, 2:52 PM EDT - Market open
Moleculin Biotech Employees
Moleculin Biotech had 17 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
17
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,980,235
Market Cap
12.49M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 17 | 0 | - | 17 | 0 |
| Dec 31, 2024 | 17 | -1 | -5.56% | 17 | 0 |
| Dec 31, 2023 | 18 | -1 | -5.26% | 18 | 0 |
| Dec 31, 2022 | 19 | 2 | 11.76% | 15 | 4 |
| Dec 31, 2021 | 17 | 2 | 13.33% | 13 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 43 |
| Imunon | 25 |
| BioCardia | 20 |
| Soligenix | 16 |
| Traws Pharma | 7 |
| Quoin Pharmaceuticals | 5 |
| Jupiter Neurosciences | 4 |
| Cadrenal Therapeutics | 4 |
MBRX News
- 14 days ago - Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout - GlobeNewsWire
- 18 days ago - Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026 - GlobeNewsWire
- 20 days ago - Moleculin to Present at 38th Annual ROTH Conference - GlobeNewsWire
- 26 days ago - Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study - GlobeNewsWire
- 6 weeks ago - Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds - GlobeNewsWire
- 6 weeks ago - Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30) - GlobeNewsWire
- 6 weeks ago - Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin - GlobeNewsWire
- 7 weeks ago - Moleculin Launches CEO Corner Platform to Share Strategic Insights - GlobeNewsWire